Lisanti Capital Growth LLC Increases Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Lisanti Capital Growth LLC increased its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 79.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 113,155 shares of the biotechnology company's stock after purchasing an additional 50,160 shares during the quarter. Corcept Therapeutics makes up approximately 1.3% of Lisanti Capital Growth LLC's portfolio, making the stock its 22nd largest position. Lisanti Capital Growth LLC owned about 0.11% of Corcept Therapeutics worth $5,237,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of CORT. Capital Performance Advisors LLP bought a new stake in shares of Corcept Therapeutics in the third quarter valued at about $25,000. Park Place Capital Corp acquired a new position in Corcept Therapeutics in the second quarter valued at approximately $32,000. Atwood & Palmer Inc. bought a new position in shares of Corcept Therapeutics in the 2nd quarter worth $35,000. Kathleen S. Wright Associates Inc. bought a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at about $36,000. Finally, Blue Trust Inc. boosted its position in shares of Corcept Therapeutics by 125.4% during the second quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company's stock worth $115,000 after purchasing an additional 1,962 shares in the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Corcept Therapeutics Trading Down 0.2 %

NASDAQ CORT traded down $0.14 during mid-day trading on Monday, reaching $59.46. 920,542 shares of the stock were exchanged, compared to its average volume of 1,189,841. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The stock has a 50 day simple moving average of $44.32 and a 200-day simple moving average of $35.83. Corcept Therapeutics Incorporated has a one year low of $20.84 and a one year high of $61.66. The stock has a market cap of $6.23 billion, a P/E ratio of 47.30 and a beta of 0.45.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.27 by $0.14. The business had revenue of $182.55 million during the quarter, compared to analysts' expectations of $171.97 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm's revenue was up 47.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.28 earnings per share. On average, analysts anticipate that Corcept Therapeutics Incorporated will post 1.31 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on CORT. Piper Sandler raised their price objective on Corcept Therapeutics from $38.00 to $67.00 and gave the company an "overweight" rating in a report on Wednesday, September 18th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $38.00 price target on shares of Corcept Therapeutics in a report on Tuesday, July 30th. StockNews.com upgraded shares of Corcept Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 31st. Sandler O'Neill reissued a "buy" rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Finally, HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Corcept Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $65.25.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, insider Gary Charles Robb sold 3,101 shares of the company's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $35.71, for a total transaction of $110,736.71. Following the transaction, the insider now owns 23,190 shares in the company, valued at approximately $828,114.90. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Corcept Therapeutics news, insider Gary Charles Robb sold 3,101 shares of the business's stock in a transaction on Monday, August 26th. The stock was sold at an average price of $35.71, for a total value of $110,736.71. Following the transaction, the insider now owns 23,190 shares of the company's stock, valued at approximately $828,114.90. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Guyer sold 3,394 shares of the business's stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $48.97, for a total transaction of $166,204.18. Following the completion of the transaction, the insider now owns 5,796 shares in the company, valued at approximately $283,830.12. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 34,101 shares of company stock valued at $1,462,517 in the last three months. Corporate insiders own 20.50% of the company's stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.